Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenicriviroc - Tobira Therapeutics

Drug Profile

Cenicriviroc - Tobira Therapeutics

Alternative Names: Cenicriviroc mesylate; CVC; TAK-652; TBR-652

Latest Information Update: 04 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute for Health Research; Takeda
  • Developer AbbVie; Charite - Universitatsmedizin Berlin; Dong-A ST; Imperial College of Science, Technology and Medicine; National Institute for Health Research; Novartis; Quantum Leap Healthcare Collaborative; Tobira Therapeutics; University of Hawaii
  • Class Amides; Anti-inflammatories; Antifibrotics; Antineoplastics; Antiretrovirals; Hepatoprotectants; Imidazoles; Nootropics; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cognition disorders; COVID 2019 infections; HIV-1 infections; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • No development reported Cancer; Cholestasis; Diabetic nephropathies; Graft-versus-host disease; Liver disorders

Most Recent Events

  • 04 Jan 2024 Discontinued - Phase-III for Non-alcoholic steatohepatitis in Slovenia, Switzerland, Switzerland, Singapore, Taiwan, Portugal, New Zealand, Romania, Russia, Peru, Norway, Mexico, Israel, Hungary, Greece, Georgia, Chile, Canada, Austria, Poland, Germany, Belgium, Latvia, Puerto Rico, USA, Australia, United Kingdom, France, Spain, Hong Kong, Italy, Argentina, Brazil, India (PO) Prior to January 2024 (AbbVie pipeline, January 2024)
  • 30 May 2023 National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with AbbVie initiates enrolment in a phase II trial for HIV-1-infection in US (NCT05630885)
  • 30 Nov 2022 AbbVie in collaboration with National Institute of Allergy and Infectious Diseases plans a phase II trial for HIV-1 infections in USA (PO) (NCT05630885)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top